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Abstract 
INTRODUCTION: We assessed the association of gamma-glutamyltransferase (GGT) with risk of 
dementia. 
METHODS: Serum GGT activity was assessed at baseline in the Kuopio Ischemic Heart Disease 
prospective cohort of 2415 relatively healthy men with good cognitive function. Correction was made for 
within-person variability in GGT levels. 
RESULTS: During an average follow-up of 22 years, 219 new cases of dementia were recorded. Serum 
GGT was log-linearly associated with risk of dementia. The hazard ratio (HR) (95% CIs) for dementia per 
1 standard deviation (SD) higher baseline loge GGT values was 1.33 (95% CI: 1.14-1.55) after adjustment 
for several established and emerging risk factors. The corresponding HR was 1.52 (95% CI: 1.22-1.89) 
after correction for within-person variability.   
DISCUSSION: GGT is positively, log-linearly, and independently associated with future risk of 
dementia in the general male population. Further research is needed to unravel the mechanistic pathways 
of GGT in the pathogenesis of dementia. 
 
Keywords: Gamma-glutamyltransferase; Risk factor; Dementia 
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1. Background 
Dementia is a vast public health problem and has been established as one of the major challenges of 
this century.[1] With the ageing global population, enormous resources will be required to care for those 
afflicted with the disease, thereby imposing a significant economic burden on health systems and society 
as a whole.[2] The global prevalence is expected to rise from 30 million in 2010 to 106 million in 
2050.[2] Though there is a direct correlation between ageing and the incidence of dementia, the 
pathogenesis of dementia is not fully understood. A number of pathways have been implicated, notably 
including inflammation and oxidative stress.[3, 4] Several pharmacological agents exist for the treatment 
of dementia, but majority of these agents have not proved beneficial in modifying the course of the 
disease.[5] Though active research is underway to develop interventions that will slow down the disease 
progress,[6] there is an urgent need to develop strategies to prevent or delay disease onset. It has been 
projected that a delay by one year in both disease onset and progression will result in nearly 9.2 million 
fewer cases of the disease by 2050.[2] 
Gamma-glutamyltransferase (GGT), a biomarker which is routinely used in clinical practice to help 
indicate potential hepatic or biliary disease, has been shown to be associated with a wide range of 
vascular disease outcomes.[7-9] Since vascular disease is associated with cognitive impairment and 
dementia,[10] serum levels of GGT might increase the risk of dementia. Given the pro-oxidant and pro-
inflammatory properties of GGT[11] and similar pathways implicated for the development of 
dementia,[3, 4] we hypothesized that GGT will be associated with an increased risk of dementia. We 
therefore aimed to evaluate in detail the nature and magnitude of the prospective association of GGT with 
risk of dementia in a population-based cohort of 2415 apparently healthy men from eastern Finland. 
Repeat measurements of GGT were performed 4 and 11 years after baseline examinations in 900 
participants to help quantify within-person variability in GGT values. In subsidiary analysis, we also 
assessed the association of GGT with the dementia subtype - Alzheimer’s disease. 
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2. Methods 
 This study followed the STROBE (STrengthening the Reporting of OBservational studies in 
Epidemiology) guidelines for reporting observational studies in epidemiology (Appendix).[12] 
 
2.1. Study population 
The study population consisted of a representative sample of men living in the city of Kuopio and its 
surrounding rural communities in eastern Finland. Subjects were participants in the Kuopio Ischemic 
Heart Disease (KIHD) risk factor study, a longitudinal population-based study designed to investigate risk 
factors for CVD and other chronic diseases.[13] Participants were 42-61 years of age during baseline exa-
minations performed between March 1984 and December 1989. Of 3433 potentially eligible and 
randomly selected men, 3235 were found to be eligible for the study. Of this number, 2682 (82.9 %) 
volunteered to participate, 186 did not respond to the invitation and 367 declined to give informed 
consent. The final cohort for the present analysis included 2415 men with no history of dementia at 
baseline and with non-missing information on serum GGT and covariates. The derivation of the analytic 
cohort is provided in Figure 1. The Research Ethics Committee of the University of Eastern Finland 
approved the study, and each participant gave written informed consent.  
 
2.2. Ascertainment of outcomes 
All dementia cases that occurred from study enrollment through 2012 were included. There were no 
losses to follow-up. In the KIHD study, all participants (using Finnish personal identification codes) are 
under continuous annual monitoring for incident dementia cases and cardiometabolic outcomes, including 
incident cases and deaths.[14] The sources of information on outcomes were based on a comprehensive 
review of hospital admission and discharge records, inpatient physician claims data, medico-legal reports, 
and by record linkage with the hospital coronary intervention, national hospital discharge and national 
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death registries. Incident coronary heart disease events were defined as nonfatal myocardial infarction, 
ischemic heart disease, coronary artery bypass grafting, and percutaneous transluminal coronary 
angioplasty according to ICD-9 codes or ICD-10 codes. For dementia screening and diagnosis, 
participants were first screened with tests of cognition, including the Mini-Mental State Examination and 
Geriatric Mental State[15] at baseline examination and every year. This was followed by further cognitive 
testing of screen-positives. Subjects suspected of having dementia were examined by neurologists, 
underwent neuropsychological testing, and magnetic resonance imaging of the brain. An independent 
committee of neurologists of the KIHD study, masked to clinical data, reviewed all potential cases of 
dementia to obtain a consensus on the diagnosis and aetiology. Participants with a diagnosis of dementia 
underwent another examination after one year to confirm the diagnosis. 
 
2.3. Measurement of risk factors 
Collection of blood specimens and the measurement of serum lipids, lipoproteins and glucose have 
been described previously.[16] Blood samples were taken between 08:00 and 10:00 hours. In addition to 
fasting, participants were instructed to abstain from drinking alcohol for at least 3 days and from smoking 
for at least 12 h prior to assessment. The serum samples were stored frozen at -80 °C for 0.2-2.5 years. 
Fasting plasma glucose (FPG) was measured by the glucose dehydrogenase method (Merck, Darmstadt, 
Germany). Serum GGT activity was measured using the kinetic method (Thermo Fisher Scientific, 
Vantaa, Finland) and C-reactive protein (CRP) with an immunometric assay (Immulite High Sensitivity 
C-Reactive Protein Assay; DPC, Los Angeles, CA, USA). Repeat measurements of GGT were performed 
4 years and 11 years after baseline examinations during a 22 year period in a random subset of 
participants. Smoking, alcohol consumption, blood pressure, use of medication, family histories, and 
baseline diseases were assessed by self-administered questionnaires as described previously.[16] Alcohol 
consumption was assessed using the Nordic Alcohol Consumption Inventory. Chronic disease diagnoses 
and medication use were checked during medical examinations by the internist. Body mass index (BMI) 
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was computed as the ratio of weight in kilograms to the square of height in metres. The energy 
expenditure of physical activity was assessed from a 12-month physical activity history modified from the 
Minnesota Leisure-Time Physical Activity Questionnaire[17] as described in detail previously.[18] 
Briefly, this detailed quantitative questionnaire deals with the most common leisure-time physical 
activities of middle-aged Finnish men (conditioning physical activity, e.g. walking, skiing, bicycling, 
swimming, rowing, ball games, etc  and nonconditioning physical activity, e.g. crafts, repairs, building, 
gardening, hunting, fishing, etc) and enables the assessment of all components of physical activity. For 
each activity performed, participants were asked to record the frequency, average duration, and intensity. 
Energy expenditure was measured for each physical activity by multiplying the metabolic index of 
activity (in metabolic equivalent*hour/week) by body weight in kilograms. Adulthood socioeconomic 
status is a summary index that combines measures of income, education, occupation, occupational 
prestige, material standard of living, and housing conditions, all of which were assessed with self-reported 
questionnaires.[19] Diabetes was defined as a fasting plasma glucose of ≥ 7.0 mmol/l or clinical diagnosis 
of diabetes with dietary, oral, or insulin treatment, or according to self-reports. A history of coronary heart 
disease (CHD) was defined as either a previous myocardial infarction, ischemic heart disease, coronary 
artery bypass grafting, percutaneous transluminal coronary angioplasty, angina pectoris or the use of 
nitroglycerin for chest pain once a week or more frequently. 
 
2.4. Statistical analysis 
Values of skewed variables (GGT and CRP) were log-transformed to achieve approximately 
symmetrical distributions. We performed descriptive analyses summarising the baseline characteristics of 
the participants. Cross-sectional associations of GGT with various risk markers were assessed using linear 
regression models adjusted for age. Time-to-event analyses were conducted using Cox proportional 
hazard models after confirming assumptions of proportionality of hazards. To quantify and correct for 
within-person variability in levels of GGT, that is, the extent to which an individual’s GGT measurements 
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vary around a long-term average level exposure (“usual levels”),[20] adjusted regression dilution ratios 
(RDRs) were estimated by regressing available repeat measurements on baseline values.[21] To 
characterize the shape of the association between GGT and risk of dementia, hazard ratios (HRs) were 
calculated within quartiles of baseline GGT values and plotted against mean GGT values within each 
quartile. Floating variances were used to calculate 95% confidence intervals for the log hazard ratio in 
each group, including the reference group, to allow for comparisons across the groups irrespective of the 
arbitrarily chosen reference category (bottom quartile)26. As the association showed a log-linear shape, 
HRs were calculated per 1 standard deviation (SD) higher loge GGT values. The SD of baseline loge GGT 
was 0.65 (equivalent to approximately 2-fold higher circulating GGT, as e0.65=1.92). In subsidiary 
analyses, HRs were also calculated by quartiles defined according to the baseline distribution of serum 
GGT values. HRs were adjusted for age, BMI, systolic blood pressure (SBP,) prevalent CHD, smoking 
status, history of diabetes mellitus, use of medications (antihypertensive agents and lipid-lowering drugs), 
total cholesterol, high-density lipoprotein cholesterol (HDL-C), alcohol consumption, socio-economic 
status, physical activity, and CRP. We performed subgroup analyses using interaction tests to assess 
statistical evidence of any differences in hazards across levels/categories of pre-specified individual level 
characteristics, including age at survey, BMI, SBP, total cholesterol, CRP, history of diabetes, smoking 
status, and history of CHD. Sensitivity analyses included (i) excluding the first five years of follow-up to 
avoid including cases with prevalent but undetected impaired cognitive function; (ii) excluding 
participants with GGT values greater than three times the upper limit of normal, given that elevated levels 
of GGT is a common reason for liver disease work-up; and (iii) excluding participants with potential fatty 
liver disease using a validated predictive index – the fatty liver index (FLI). The FLI - a simple algorithm 
for predicting fatty liver - is based on BMI, waist circumference, triglycerides, and GGT, and has a 
diagnostic accuracy ranging from 0.72 to 0.84%.[22, 23] All statistical analyses were conducted using 
Stata version 14 (Stata Corp, College Station, Texas). 
 
8 
 
 
3. Results 
3.1. Baseline characteristics and correlates of gamma-glutamyltransferase 
Table 1 summarizes baseline characteristics of the 2415 participants. The mean age of the participants 
was 53 (SD 5) years. Median (interquartile range) GGT value was 20 (15-33) U/L. During an average 
follow-up of 22 years, there were 219 new cases of dementia (annual rate 4.19/1,000 person-years at risk; 
95% CI 3.67 to 4.79). Of the total number of dementia cases, 132 were cases due to Alzheimer’s disease. 
Serum GGT values were weakly to moderately and positively correlated with physical measures (BMI, 
blood pressure, and physical activity) and with several lipid, metabolic, and inflammation markers (CRP). 
Weak inverse correlations were observed for age (r = -0.03) and HDL-C (r = -0.03). Baseline GGT values 
were higher in people with diabetes compared with people without diabetes, higher in current smokers 
compared with non-smokers, and higher in people on antihypertensive medication compared with people 
not on antihypertensive medication (Table 2). 
 
3.2. Correction for within-person variability  
Repeat measurements of GGT taken 4 years and 11 years after baseline examinations over 22 years 
were available in a random sample of 900 participants. Overall, the regression RDR of loge GGT, 
adjusted for age, was 0.69 (95% CI: 0.63 to 0.74), suggesting that the associations using one-off or 
baseline measurements of GGT with dementia could under-estimate the association by [(1/0.69)-1]*100 = 
45%.  
 
3.3. Gamma-glutamyltransferase and risk of dementia 
Rates of dementia per 1000 person-years of follow-up across quartiles of GGT were 5.36 (95% CI: 
4.17 to 6.89) for the fourth quartile, 4.37 (95% CI: 3.39 to 5.64) for the third quartile, 3.66 (95% CI: 2.68 
to 4.99) for the second quartile, and 3.59 (95% CI: 2.78 to 4.64) for the first quartile. Cumulative hazard 
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curves demonstrated a greater risk of dementia among males in the top quartile of GGT levels compared 
to those in the bottom quartile (P = 0.01 for log-rank test; Figure 2). Baseline and usual GGT values were 
log-linearly associated with risk of dementia in analyses adjusted for age, BMI, SBP, history of CHD, 
smoking status, history of diabetes mellitus, use of antihypertensive agents and lipid-lowering drugs, 
alcohol consumption, socio-economic status, and physical activity (Figure 3). The age-adjusted HR per 1 
SD change in baseline loge GGT value was 1.44 (95% CI: 1.26 to 1.65; P < 0.001), which was somewhat 
attenuated following further adjustment for several established risk factors 1.32 (95% CI: 1.14 to 1.55; P 
< 0.001). The observed association did not change after further adjustment for CRP 1.33 (95% CI: 1.14 to 
1.55; P < 0.001). The corresponding HRs per 1 SD change in usual loge GGT values were 1.70 (95% CI: 
1.40 to 2.07; P < 0.001), 1.51 (95% CI: 1.21 to 1.88; P < 0.001), and 1.52 (95% CI: 1.22 to 1.89; P < 
0.001) respectively (Table 3). The HRs remained consistent after further adjustment for incident coronary 
events (Table 3).The significant associations were maintained in analyses by quartiles of the baseline 
distribution of GGT values. HRs were similar in analyses that excluded (i) the first five years of follow-
up; (ii) participants with GGT values greater than three times the upper limit of normal; and (iii) 
participants with potential fatty liver disease (Table 4). The associations generally did not vary 
significantly by levels or categories of several clinically relevant characteristics and other risk markers, 
except for suggestion of effect modification by age (P for interaction = 0.032) and history of CHD (P for 
interaction = 0.046)  (Figure 4). Significant positive associations were observed in older individuals 
(aged 54 years and above) and individuals with a history of CHD compared to non-significant 
associations in younger individuals and those without a history of CHD respectively (Figure 4).  
In separate analyses for Alzheimer’s disease, the positive association of GGT with Alzheimer’s 
disease in age-adjusted analyses was attenuated upon further adjustment for several established risk 
factors (Table 5).   
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4. Discussion 
4.1. Key findings 
In this large-scale population of middle-aged to older Finnish men, we have for the first time assessed 
the shape, magnitude, independence, and specificity of the prospective association of both baseline and 
usual values of GGT with risk of dementia (including the specific outcome of Alzheimer’s disease) in a 
single comprehensive investigation.  In analyses adjusted for age and established risk factors, we 
observed an approximately log-linear association of GGT with risk of dementia. The association did not 
materially change on further adjustment for CRP and incident coronary events. Except for suggestion of 
effect modification by age and history of CHD, the overall findings remained consistent across several 
categories and levels of risk markers for dementia. There were more extreme results in studies conducted 
among older individuals, consistent with established evidence that increasing age is the most important 
risk factor for dementia.[24] A stronger association with people with a history of CHD was also 
demonstrated, also consistent with evidence that vascular disease is associated with increased risk of 
dementia.[10] The associations remained robust in several sensitivity analyses.  
 
4.2. Possible explanations for findings 
A growing body of evidence suggests that serum levels of GGT may be associated with a wide range 
of disease outcomes. Several prospective studies have demonstrated associations between GGT and risk 
of vascular and non-vascular outcomes.[7-9, 25-27] Several mechanisms have been postulated for these 
associations and these include the pro-inflammatory and pro-oxidant activities of GGT[11], as well as its 
direct involvement in atheromatous plaque formation.[28, 29] Though the pathogenesis of dementia has 
not been completely elucidated, mechanistic research provides strong support for inflammatory and 
oxidative processes.[3, 4, 30] Our results are therefore biologically plausible as GGT mediates these 
processes. Gamma-glutamyltransferase plays a major role in glutathione (the major thiol antioxidant in 
the body) metabolism, generating reactive oxygen species, which contribute to the aging process and 
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pathogenesis of age-related neurodegenerative diseases such as dementia.[31, 32] Additionally, elevated 
GGT levels are associated with atherosclerosis, which has also been implicated as an underlying link in 
the pathogenesis of dementia.[10]  
 
4.3. Implications of findings 
Our findings are relevant as they provide further insight on putative risk factors that may inform our 
understanding of neurodegenerative disorders. The results highlight a potential deleterious role of serum 
GGT levels on the risk of dementia. Till date, there is still no cure for dementia and only pharmacological 
and non-pharmacological agents exist to alleviate the cognitive and behavioural symptoms of the disease. 
Therefore, potential risk factors which may have causal or predictive relevance to dementia could help 
tailor preventive and therapeutic interventions. Dementia has a multifactorial aetiology and current 
evidence suggests inflammation and oxidative stress as major hallmarks in the pathogenesis of dementia. 
Given the role of GGT as both an inflammatory and oxidative mediator, there remains a possibility that 
lowering levels of GGT may decrease the risk of future dementia. Individuals with elevated GGT levels 
might benefit from nutritional and lifestyle modification (e.g., weight loss and physical activity[33]) that 
decrease GGT levels. Our findings are among the first in this research area and therefore is a topic for 
further investigation. Gamma-glutamyltransferase remains a promising though unproven strategy in the 
prevention of chronic diseases, therefore further research is warranted to investigate any potential 
therapeutic implications of GGT in dementia. 
 
4.4. Strengths and limitations 
Our study has several strengths. It is the first longitudinal study so far on the association between GGT 
and dementia. The large sample was selected to be a nationally representative population-based sample of 
middle-aged men, was well characterised, involved a high participation rate and there were no losses 
during follow-up, minimising the risk of selection bias. To obtain reliable data, baseline measurements of 
12 
 
GGT and other covariates were made in a relatively healthy cohort of middle-aged individuals with good 
cognitive function, therefore limiting any possibilities of reverse-causation bias. Participants have been 
prospectively monitored using established databases for hospital admissions including out-of-hospital 
outcome events, supplemented with reliable data on a comprehensive panel of lifestyle and biological 
markers to allow adequate adjustment for potential confounding, enabling reliable assessments of the 
associations. The mean follow-up period in this study was sufficiently long to ascertain the risk for 
dementia in the general population settings. Serial measurements of GGT made within a subset of 
individuals over time were available, enabling quantification of the extent of within-person variability 
over the long period of follow-up. However, studies are needed with repeat measurements of GGT in 
larger numbers of participants to assess GGT variability in greater detail. Our study also has some 
limitations. There might be the possibility of selection bias because about 17% of participants declined to 
participate in the study and 8% of eligible subjects did not have GGT measurements; however, this may 
be unlikely since potential participants for the KIHD study included men from an ethnically and 
genetically homogeneous population[13] and the number of participants without GGT measurements 
represented only a very small proportion of the total sample. In addition, as with most observational 
studies of this kind, it is not uncommon to record a small proportion of participants who decline to 
participate in the study. The participation rate was still rather high and the population representative. Our 
analyses focused on all types of dementia and Alzheimer’s disease only, since reliable data for other 
specific dementia subtypes such as vascular dementia were not available. The KIHD study involved 
prolonged blood storage which could underestimate the associations, however, GGT is not known to be 
influenced by prolonged storage or repeated freeze-thaw cycles.[34] The KIHD study included only 
middle-aged to older Caucasian men and cannot necessarily be extrapolated to women, the young, 
elderly, and other ethnicities. Measurements of other liver function enzymes such as the 
aminotransferases were not made in the KIHD study, thus preventing comparisons of the separate and 
joint associations of these enzymes with dementia risk. 
13 
 
Though a comprehensive panel of confounders was taken into account to ensure the validity of our 
results, potential residual confounding due to errors in risk marker measurements and other  unmeasured 
confounders (such as other liver enzymes and biliary and liver diseases) cannot be entirely ruled out in 
these analyses. However, in several sensitivity analyses, we excluded participants with GGT values 
greater than three times the upper limits of normal and participants with potential fatty liver disease as 
predicted by the FLI, thereby minimising potential bias due to undiagnosed liver disease such at baseline. 
In addition, we did not have complete genetic data, which precluded further analyses such as adjusting for 
the APOE gene (encoding apolipoprotein E), a major genetic risk factor for age-related cognitive decline 
and Alzheimer’s disease.[35] 
 
4.5. Conclusions 
Available evidence suggests that GGT is positively, log-linearly, and independently associated with 
future risk of dementia over two decades in the general male population. Further research is needed to 
replicate these findings and help unravel the mechanistic pathways of GGT in the pathogenesis of 
dementia.  
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Figure Legends 
 
Fig.1. Derivation of analytic sample 
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GGT, gamma-glutamyltransferase 
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Fig. 2. Cumulative hazard curves for dementia by quartiles of gamma-glutamyltransferase 
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gamma-glutamyltransferase 
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Fig. 3. Hazard ratios for dementia, by quartiles of baseline and usual values of gamma-
glutamyltransferase 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, history of coronary 
heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents and lipid-
lowering drugs), total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, socio-
economic status, and physical activity; GGT, gamma-glutamyltransferase 
 
 
 
 
21 
 
Fig. 4. Hazard ratios for baseline and usual values of gamma-glutamyltransferase and dementia risk by 
several participant level characteristics 
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A, baseline levels of GGT; B, usual levels of GGT; Hazard ratios were adjusted for age, body mass index, 
systolic blood pressure, history of coronary heart disease, smoking status, history of diabetes, use of 
medications (antihypertensive agents and lipid-lowering drugs), total cholesterol, high-density lipoprotein 
cholesterol, alcohol consumption, socio-economic status, and physical activity; CI, confidence interval; 
GGT, gamma-glutamyltransferase; HR, hazard ratio; SD, standard deviation; SBP, systolic blood 
pressure; *, P-value for interaction 
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Table 1. Baseline participant characteristics 
 
 
 
 
Overall (N=2415) 
Mean (SD) or n (%) 
 
Without Dementia 
(N=2196) 
Mean (SD) or n (%) 
 
With Dementia 
(N=219) 
Mean (SD) or % 
 
 
P-value 
Loge GGT (U/L) 3.13 (0.65) 3.12 (0.64) 3.22 (0.73) 0.044 
 
    
Questionnaire/Prevalent conditions     
Age at survey (years) 53.2 (5.0) 53.0 (5.1) 55.8 (3.3) < 0.0001 
Alcohol consumption (g/week) 75.6 (136.5) 74.7 (137.6) 84.1 (125.6) 0.335 
History of diabetes 99 (4.1) 68 (4.1) 14 (10.3) 0.155 
Current smokers 764 (31.6) 515 (31.3) 62 (45.6) 0.030 
History of CHD 620 (25.7) 334 (20.3) 57 (41.9) 0.540 
Use of anti-hypertensives 542 (22.4) 287 (17.5) 38 (27.9) 0.007 
Medication for dyslipidemia 16 (0.7) 11 (0.7) 0 (0.0) 0.694 
     
Physical measurements     
BMI (kg/m2) 26.9 (3.6) 26.9 (3.6) 27.1 (3.4) 0.253 
SBP (mmHg) 134 (17) 134 (17) 135 (16) 0.475 
DBP (mmHg) 89 (11) 89 (11) 89 (10) 0.369 
Physical activity (kj/day) 1545 (1482) 1547 (1509) 1521 (1180) 0.802 
     
Lipid markers     
Total cholesterol (mmol/l) 5.92 (1.09) 5.89 (1.09) 6.09 (1.05) 0.015 
HDL-C (mmol/l) 1.30 (0.30) 1.29 (0.30) 1.36 (0.35) 0.002 
Loge triglycerides (mmol/l) 0.12 (0.51) 0.12 (0.51) 0.13 (0.52) 0.804 
     
Metabolic and inflammatory 
markers 
    
Fasting plasma glucose (mmol/l) 5.37 (1.28) 5.38 (1.32) 5.22 (0.85) 0.088 
Serum creatinine (µmol/1) 89.6 (20.8) 89.7 (21.4) 88.6 (13.0) 0.442 
Loge CRP (mg/l) 0.34 (0.97) 0.35 (0.97) 0.26 (0.97) 0.211 
 
 BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; GGT, gamma-glutamyltransferase 
HDL-C, high-density lipoprotein cholesterol; SD, standard deviation; SBP, systolic blood pressure 
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Table 2. Cross-sectional correlates of gamma-glutamyltransferase 
 Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in GGT levels 
per 1 SD higher or compared to reference 
category of correlate‡ 
Loge GGT (U/L) - - 
 
  
Questionnaire/Prevalent conditions   
Age at survey (years) -0.03 (-0.07, 0.01) -2% (-5, 1) 
Alcohol consumption (g/week) 0.29 (0.26, 0.33)*** 21% (18, 24)*** 
History of diabetes   
    No - Ref 
    Yes - 55% (36, 76)*** 
Smoking status   
    Other - Ref 
    Current - 6% (-0, 12) 
History of CHD   
    No - Ref 
    Yes - 18% (12, 26)*** 
Use of anti-hypertensives   
    No - Ref 
    Yes - 28% (20, 36)*** 
Medication for dyslipidemia   
    No - Ref 
    Yes - 17% (-15, 62) 
   
Physical measurements   
BMI (kg/m2) 0.34 (0.31, 0.38)*** 25% (22, 28)*** 
SBP (mmHg) 0.23 (0.19, 0.26)*** 16% (13, 19)*** 
DBP (mmHg) 0.23 (0.19, 0.27)*** 16% (13, 19)*** 
Physical activity (kj/day) 0.03 (-0.01, 0.07) 2% (-1, 5)*** 
   
Lipid markers   
Total cholesterol (mmol/l) 0.10 (0.06, 0.14)*** 7% (4, 9)*** 
HDL-C (mmol/l) -0.03 (-0.07, 0.01) -2% (-4, 1) 
Loge triglycerides (mmol/l) 0.26 (0.22, 0.30)*** 19% (16, 22)*** 
   
Metabolic and inflammatory markers   
Fasting plasma glucose (mmol/l) 0.20 (0.16, 0.24)*** 14% (11, 17)*** 
Serum creatinine (µmol/1) -0.00 (-0.04, 0.04) -0% (-3, 3) 
Loge C-reactive protein (mg/l) 0.26 (0.23, 0.30)*** 19% (16, 22)*** 
 
 BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; GGT, 
gamma-glutamyltransferase; SD, standard deviation; SBP, systolic blood pressure; asterisks indicate the level of statistical significance: *, 
p<0.05; **, p<0.01; ***, p<0.001, †Pearson correlation coefficients between loge GGT and the row variables; ‡, Percentage change in GGT 
levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean GGT levels for the category versus 
the reference) adjusted for age  
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Table 3. Associations of baseline and usual values of gamma-glutamyltransferase with dementia 
 
 
 Events/Total Model 1  Model 2  Model 3  Model 4  
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Baseline GGT 
Per 1 SD increase in 
loge GGT 
219 / 2415 1.44 (1.26 to 1.65) < 0.001 1.32 (1.14 to 1.55) < 0.001 1.33 (1.14 to 1.55) < 0.001 1.33 (1.14 to 1.55) < 0.001 
Quartile 1 59 / 718 Ref  Ref  Ref  Ref  
Quartile 2 40 / 498 1.07 (0.72 to 1.60) 0.742 1.01 (0.67 to 1.52) 0.962 1.01 (0.67 to 1.53) 0.949 1.00 (0.66 to 1.51) 0.991 
Quartile 3 59 / 629 1.36 (0.95 to 0.95) 0.098 1.21 (0.83 to 1.76) 0.313 1.22 (0.84 to 1.77) 0.306 1.21 (0.83 to 1.77) 0.319 
Quartile 4 61 / 570 2.01 (1.40 to 2.88) < 0.001 1.58 (1.05 to 2.37) 0.027 1.59 (1.06 to 2.39) 0.027 1.58 (1.05 to 2.38) 0.030 
Usual GGT 
Per 1 SD increase in 
loge GGT 
219 / 2415 1.70 (1.40 to 2.07) < 0.001 1.51 (1.21 to 1.88) < 0.001 1.52 (1.22 to 1.89) < 0.001 1.51 (1.21 to 1.89) < 0.001 
Quartile 1 59 / 718 Ref  Ref  Ref  Ref  
Quartile 2 40 / 498 1.10 (0.61 to 1.99) 0.742 1.01 (0.56 to 1.85) 0.962 1.02 (0.56 to 1.87) 0.949 1.00 (0.55 to 1.82) 0.991 
Quartile 3 59 / 629 1.57 (0.92 to 2.67) 0.098 1.33 (0.77 to 2.30) 0.313 1.34 (0.77 to 2.32) 0.306 1.32 (0.76 to 2.28) 0.319 
Quartile 4 61 / 570 2.79 (1.65 to 4.74) < 0.001 1.96 (1.08 to 3.56) 0.027 1.98 (1.08 to 3.61) 0.027 1.93 (1.07 to 3.50) 0.030 
 
GGT, gamma-glutamyltransferase; 1 standard deviation higher loge GGT was approximately equivalent to two-fold higher GGT levels. 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, history of coronary heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents 
and lipid-lowering drugs), total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, socio-economic status, and physical activity 
Model 3: Model 2 plus C-reactive protein 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
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Table 4. Hazard ratios for dementia with exclusion of first five years of follow-up, participants with GGT values greater than three times the upper 
limit of normal, and participants with potential fatty liver disease 
 
 
 Events/Total Model 1  Model 2  Model 3  Model 4  
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Excluding the first five 
years of follow-up 
217 / 2297 1.42 (1.24 to 1.63) < 0.001 1.31 (1.12 to 1.53) 0.001 1.32 (1.13 to 1.54) < 0.001 1.31 (1.13 TO 1.54) 0.001 
Excluding participants 
with GGT values 
greater than three times 
the upper limit of 
normal 
218 / 2414 1.41 (1.23 to 1.63) < 0.001 1.30 (1.11 to 1.53) 0.001 1.31 (1.12 to 1.53) 0.001 1.30 (1.11 to 1.53) 0.001 
Excluding participants 
with potential fatty liver 
disease 
217 / 2404 1.44 (1.25 to 1.65) < 0.001 1.32 (1.14 to 1.54) < 0.001 1.33 (1.14 to 1.55) < 0.001 1.33 (1.14 to 1.55) < 0.001 
 
GGT, gamma-glutamyltransferase; hazard ratios were modelled per 1 standard deviation higher loge GGT (approximately equivalent to two-fold higher GGT levels) 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, history of coronary heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents 
and lipid-lowering drugs), total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, socio-economic status, and physical activity 
Model 3: Model 2 plus C-reactive protein 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
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Table 5. Associations of baseline and usual values of gamma-glutamyltransferase with Alzheimer’s disease 
 
 
 Events/Total Model 1  Model 2  Model 3  Model 4  
  Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Baseline GGT 
Per 1 SD increase 
in loge GGT 
132 / 2415 1.34 (1.11 to 1.60) 0.002 1.22 (0.99 to 1.50) 0.061 1.24 (1.01 to 1.53) 0.042 1.24 (1.01 to 1.53) 0.045 
Quartile 1 41 / 718 Ref  Ref  Ref  Ref  
Quartile 2 21 / 498 0.80 (0.47 to 1.36) 0.412 0.74 (0.43 to 1.26) 0.261 0.76 (0.44 to 1.29) 0.308 0.75 (0.44 to 1.28) 0.288 
Quartile 3 37 / 629 1.22 (0.78 to 1.90) 0.383 1.05 (0.66 to 1.67) 0.828 1.08 (0.68 to 1.73) 0.735 1.08 (0.68 to 1.72) 0.748 
Quartile 4 33 / 570 1.60 (1.01 to 2.54) 0.045 1.20 (0.71 to 2.02) 0.487 1.25 (0.74 to 2.11) 0.408 1.24 (0.73 to 2.09) 0.428 
Usual GGT 
Per 1 SD increase 
in loge GGT 
132 / 2415 1.52 (1.17 to 1.98) 0.002 1.33 (0.99 to 1.80) 0.061 1.37 (1.01 to 1.85) 0.042 1.37 (1.01 to 1.85) 0.045 
Quartile 1 41 / 718 Ref  Ref  Ref  Ref  
Quartile 2 21 / 498 0.72 (0.33 to 1.57) 0.412 0.64 (0.29 to 1.40)  0.261 0.66 (0.30 to 1.46) 0.308 0.65 (0.30 to 1.43) 0.288 
Quartile 3 37 / 629 1.34 (0.70 to 2.58) 0.383 1.08 (0.55 to 2.13) 0.828 1.13 (0.57 to 2.24) 0.735 1.12 (0.57 to 2.20) 0.748 
Quartile 4 33 / 570 2.00 (1.02 to 3.93) 0.045 1.31 (0.61 to 2.82) 0.487 1.39 (0.64 to 3.00) 0.408 1.36 (0.63 to 2.92) 0.428 
 
GGT, gamma-glutamyltransferase; 1 standard deviation higher loge GGT was approximately equivalent to two-fold higher GGT levels. 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, history of coronary heart disease, smoking status, history of diabetes, use of medications (antihypertensive agents 
and lipid-lowering drugs), total cholesterol, high-density lipoprotein cholesterol, alcohol consumption, socio-economic status, and physical activity 
Model 3: Model 2 plus C-reactive protein 
Model 4: Model 3 plus incident coronary heart disease as a time-dependent covariate 
 
 
 
